These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16706651)

  • 1. Emerging strategies for the treatment of hereditary metabolic storage disorders.
    Brady RO
    Rejuvenation Res; 2006; 9(2):237-44. PubMed ID: 16706651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
    J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
    Brady RO
    Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
    Germain DP; Fan JQ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaucher disease: multiple lessons from a single gene disorder.
    Beutler E
    Acta Paediatr Suppl; 2006 Apr; 95(451):103-9. PubMed ID: 16720474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical chaperones--a new concept in drug research.
    Kolter T; Wendeler M
    Chembiochem; 2003 Apr; 4(4):260-4. PubMed ID: 12672104
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current therapeutic strategies in lysosomal disorders].
    Kaminsky P; Lidove O
    Presse Med; 2014 Nov; 43(11):1174-84. PubMed ID: 24863660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaucher disease and the clinical experience with substrate reduction therapy.
    Zimran A; Elstein D
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.